Prasinezumab
Prasinezumab is an investigational synuclein antibody studied mainly in Parkinson’s disease. It is not an approved dementia medicine.
Overview
Listed as a same-target neighbour for Lewy-body biology. Parkinson’s trial results do not equal a dementia indication. Trial-only access.
Investigational antibody against aggregated alpha-synuclein (primarily Parkinson’s programmes). Connects to Alpha-synuclein.
1.Prasinezumab binds Alpha-synuclein.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Prasinezumab" OR ABSTRACT:"Prasinezumab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Prasinezumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentRivastigmine
Shares Parkinson’s disease dementia, Dementia with Lewy bodies and the tag dementia-atlas.
- TargetAcetylcholinesterase
Shares Parkinson’s disease dementia, Dementia with Lewy bodies and the tag dementia-atlas.
- TrialTRONTIER 2 (trontinemab Phase 3)
Shares Roche and the tag dementia-atlas.
- TreatmentTrontinemab
Shares Roche and the tag dementia-atlas.
- DiagnosisDementia (umbrella)
Shares Parkinson’s disease dementia, Dementia with Lewy bodies and the tag dementia-atlas.
- TechnologyCholinesterase inhibitors
Shares Dementia with Lewy bodies and the tag dementia-atlas.
- BottleneckWrong-subtype treatment
Shares Dementia with Lewy bodies and the tag dementia-atlas.
- DiagnosisAlzheimer’s disease
Shares Roche and the tag dementia-atlas.